Anti-CD3ε mAb improves thymic architecture and prevents autoimmune manifestations in a mouse model of Omenn syndrome: Therapeutic implications

Blood

Volumn 120, Issue 5, 2012, Pages 1005-1014

  Marrella, Veronica ^a,b   Poliani, Pietro L ^c   Fontana, Elena ^c   Casati, Anna ^d   Maina, Virginia ^a,b   Cassani, Barbara ^a,b   Ficara, Francesca ^a,b   Cominelli, Manuela ^c   Schena, Francesca ^e   Paulis, Marianna ^a,b   Traggiai, Elisabetta ^e   Vezzoni, Paolo ^a,b   Grassi, Fabio ^d,f   Villa, Anna ^a,g  

^a Milan Unit   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

^d INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Switzerland)

^e G GASLINI INSTITUTE   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

^g SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOIMMUNE REGULATOR PROTEIN; MONOCLONAL ANTIBODY CD3; MONOCLONAL ANTIBODY CD3EPSILON; RAG2 PROTEIN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG MECHANISM; MOUSE; NEWBORN; NONHUMAN; OMENN SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYMPTOM; THYMUS; TREATMENT OUTCOME;

EID: 84864569919     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-01-406827     Document Type: Article

References (46)

1. Omenn GS. Familial reticuloendotheliosis with eosinophilia. N Engl J Med. 1965;273:427-432.
2. Villa A, Santagata S, Bozzi F, et al. Partial V(D)J recombination activity leads to Omenn syndrome. Cell. 1998;93(5):885-896. (Pubitemid 28257593)
3. Villa A, Santagata S, Bozzi F, Imberti L, Notarangelo LD. Omenn syndrome: a disorder of Rag1 and Rag2 genes. J Clin Immunol. 1999; 19(2):87-97. (Pubitemid 29187924)
4. Brugnoni D, Airo P, Facchetti F, et al. In vitro cell death of activated lymphocytes in Omenn's syndrome. Eur J Immunol. 1997;27(11):2765-2773. (Pubitemid 27478341)
5. de Saint-Basile G, Le Deist F, de Villartay JP, et al. Restricted heterogeneity of T lymphocytes in combined immunodeficiency with hypereosinophilia (Omenn's syndrome). J Clin Invest. 1991;87(4):1352-1359.
6. Rieux-Laucat F, Bahadoran P, Brousse N, et al. Highly restricted human T cell repertoire in peripheral blood and tissue-infiltrating lymphocytes in Omenn's syndrome. J Clin Invest. 1998;102(2):312-321. (Pubitemid 28335190)
7. Signorini S, Imberti L, Pirovano S, et al. Intrathymic restriction and peripheral expansion of the T-cell repertoire in Omenn syndrome. Blood. 1999;94(10):3468-3478. (Pubitemid 29536142)
8. Cavazzana-Calvo M, Andre-Schmutz I, Dal Cortivo L, Neven B, Hacein-Bey-Abina S, Fischer A. Immune reconstitution after haematopoietic stem cell transplantation: obstacles and anticipated progress. Curr Opin Immunol. 2009;21(5):544-548.
9. Gozdzik J. Rapid full engraftment and successful immune reconstitution after allogeneic hamatopoietic stem cell transplantation with reduced intensity conditioning in Omenn syndrome. Pediatr Transplant. 2009;13(6):760-765.
10. Mazzolari E, Moshous D, Forino C, et al. Hematopoietic stem cell transplantation in Omenn syndrome: a single-center experience. Bone Marrow Transplant. 2005;36(2):107-114. (Pubitemid 41030625)
11. Corneo B, Moshous D, Gungor T, et al. Identical mutations in RAG1 or RAG2 genes leading to defective V(D)J recombinase activity can cause either T-B-severe combined immune deficiency or Omenn syndrome. Blood. 2001;97(9):2772-2776.
12. Villa A, Sobacchi C, Notarangelo LD, et al. V(D)J recombination defects in lymphocytes due to RAG mutations: severe immunodeficiency with a spectrum of clinical presentations. Blood. 2001;97(1):81-88. (Pubitemid 32061245)
13. Marrella V, Poliani PL, Casati A, et al. A hypomorphic R229Q Rag2 mouse mutant recapitulates human Omenn syndrome. J Clin Invest. 2007;117(5):1260-1269. (Pubitemid 46718414)
14. Cassani B, Poliani PL, Marrella V, et al. Homeostatic expansion of autoreactive immunoglobulinsecreting cells in the Rag2 mouse model of Omenn syndrome. J Exp Med. 2010;207(7):1525-1540.
15. Cavadini P, Vermi W, Facchetti F, et al. AIRE deficiency in thymus of 2 patients with Omenn syndrome. J Clin Invest. 2005;115(3):728-732. (Pubitemid 40322248)
16. Poliani PL, Facchetti F, Ravanini M, et al. Early defects in human T-cell development severely affect distribution and maturation of thymic stromal cells: possible implications for the pathophysiology of Omenn syndrome. Blood. 2009;114(1):105-108.
17. Anderson M. Aire and T cell development. Curr Opin immunol. 2011;23(2):198-206.
18. Kyewski B, Klein L. A central role for central tolerance. Annu Rev Immunol. 2006;24:571-606.
19. Honig M, Schwarz K. Omenn syndrome: a lack of tolerance on the background of deficient lymphocyte development and maturation. Curr Opin Rheumatol. 2006;18(4):383-388. (Pubitemid 44297284)
20. Notarangelo LD, Gambineri E, Badolato R. Immunodeficiencies with autoimmune consequences. Adv Immunol. 2006;89:321-370. (Pubitemid 44294561)
21. Jacobs H, Vandeputte D, Tolkamp L, de Vries E, Borst J, Berns A. CD3 components at the surface of pro-T cells can mediate pre-T cell development in vivo. Eur J Immunol. 1994;24(4):934-939. (Pubitemid 24093791)
22. Porcellini S, Panigada M, Grassi F. Molecular and cellular aspects of induced thymus development in recombinase-deficient mice. Eur J Immunol. 1999;29(8):2476-2483. (Pubitemid 29378117)
23. -/- mice in the absence of TCR beta chain expression. Int Immunol. 1994;6(7):995-1001.
24. Leo O, Foo M, Sachs DH, Samelson LE, Bluestone JA. Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc Natl Acad Sci U S A. 1987;84(5):1374-1378. (Pubitemid 17027356)
25. Poliani PL, Vermi W, Facchetti F. Thymus microenvironment in human primary immunodeficiency diseases. Curr Opin Allergy Clin Immunol. 2009;9(6):489-495.
26. Anderson G, Jenkinson EJ, Rodewald HR. A roadmap for thymic epithelial cell development. Eur J Immunol. 2009;39(7):1694-1699.
27. Takahama Y. Journey through the thymus: stromal guides for T-cell development and selection. Nat Rev Immunol. 2006;6(2):127-135. (Pubitemid 43361588)
28. Hikosaka Y, Nitta T, Ohigashi I, et al. The cytokine RANKL produced by positively selected thymocytes fosters medullary thymic epithelial cells that express autoimmune regulator. Immunity. 2008;29(3):438-450.
29. Grassi F, Barbier E, Porcellini S, von Boehmer H, Cazenave PA. Surface expression and functional competence of CD3-independent TCR zetachains in immature thymocytes. J Immunol. 1999;162(5):2589-2596. (Pubitemid 29309278)
30. Ferran C, Sheehan K, Dy M, et al. Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation. Eur J Immunol. 1990;20(3):509-515. (Pubitemid 20101288)
31. Marichal T, Ohata K, Bedoret D, et al. DNA released from dying host cells mediates aluminum adjuvant activity. Nat Med. 2011;17(8):996-1002.
32. Mathieu N, Spicuglia S, Gorbatch S, et al. Assessing the role of the T cell receptor beta gene enhancer in regulating coding joint formation during V(D)J recombination. J Biol Chem. 2003;278(20):18101-18109. (Pubitemid 36799423)
33. Naspetti M, Aurrand-Lions M, DeKoning J, et al. Thymocytes and RelB-dependent medullary epithelial cells provide growth-promoting and organization signals, respectively, to thymic medullary stromal cells. Eur J Immunol. 1997;27(6):1392-1397. (Pubitemid 27254830)
34. Ozcan E, Notarangelo LD, Geha RS. Primary immune deficiencies with aberrant IgE production. J Allergy Clin Immunol. 2008;122(6):1054-1062; quiz 1063-1054.
35. Cosimi AB, Colvin RB, Burton RC, et al. Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts. N Engl J Med. 1981;305(6):308-314. (Pubitemid 11051753)
36. Flechner SM, Goldfarb DA, Fairchild R, et al. A randomized prospective trial of low-dose OKT3 induction therapy to prevent rejection and minimize side effects in recipients of kidney transplants. Transplantation. 2000;69(11):2374-2381. (Pubitemid 30409006)
37. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. Ortho Multicenter Transplant Study Group. N Engl J Med. 1985;313(6):337-342.
38. Chatenoud L, Thervet E, Primo J, Bach JF. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci U S A. 1994;91(1):123-127. (Pubitemid 24018655)
39. Chatenoud L. Anti-CD3 antibodies: towards clinical antigen-specific immunomodulation. Curr Opin Pharmacol. 2004;4(4):403-407. (Pubitemid 38987069)
40. Herold KC, Gitelman S, Greenbaum C, et al. Treatment of patients with new onset type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 years. Clin Immunol. 2009;132(2):166-173.
41. Utset TO, Auger JA, Peace D, et al. Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J Rheumatol. 2002;29(9):1907-1913. (Pubitemid 34988699)
42. Steffens S, Burger F, Pelli G, et al. Short-term treatment with anti-CD3 antibody reduces the development and progression of atherosclerosis in mice. Circulation. 2006;114(18):1977-1984. (Pubitemid 44665393)
43. Bluestone JA, Auchincloss H, Nepom GT, Rotrosen D, St Clair EW, Turka LA. The Immune Tolerance Network at 10 years: tolerance research at the bedside. Nat Rev Immunol. 2010;10(11):797-803.
44. You S, Chatenoud L. New generation CD3 monoclonal antibodies: are we ready to have them back in clinical transplantation? Curr Opin Organ Transplant. 2010;15(6):720-724.
45. Chatenoud L. Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies? Nat Rev Endocrinol. 2010;6(3):149-157.
46. Chatenoud L. Progress towards the clinical use of CD3 monoclonal antibodies in the treatment of autoimmunity. Curr Opin Organ Transplant. 2009;14(4):351-356.